Published in Antimicrob Agents Chemother on March 01, 1994
Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev (1999) 12.90
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother (2001) 2.03
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev (1996) 1.85
Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother (1995) 1.48
Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother (2006) 1.04
Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrob Agents Chemother (2004) 0.98
Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother (2007) 0.89
Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats. Antimicrob Agents Chemother (2000) 0.84
Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits. Antimicrob Agents Chemother (2001) 0.83
Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother (2000) 0.82
Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother (1998) 0.78
Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother (2002) 0.77
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49
Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med (1984) 3.07
Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis (1989) 2.08
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 1.93
Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother (1991) 1.88
Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med (1986) 1.81
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect (1990) 1.58
Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol (1989) 1.52
Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother (1991) 1.49
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother (1991) 1.39
Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol (1991) 1.32
Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med (1988) 1.18
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother (1992) 1.14
Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother (1991) 1.11
Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann N Y Acad Sci (1985) 1.00
Treatment of experimental murine candidiasis with liposome-associated amphotericin B. Sabouraudia (1984) 0.94
Factors associated with fatal hemoptysis in cancer patients. Chest (1988) 0.89
Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med (1986) 0.87
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science (1998) 6.53
Variance components testing in the longitudinal mixed effects model. Biometrics (1994) 6.26
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
HIV infection in homosexual and bisexual men 18 to 29 years of age: the San Francisco Young Men's Health Study. Am J Public Health (1994) 5.18
MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev (1996) 4.59
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal (2000) 3.72
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci (1988) 3.49
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Sabin, Salk, or sequential? Lancet (1996) 3.35
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med (1982) 3.08
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med (1999) 3.02
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol (2008) 2.95
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Human immunodeficiency virus infection in children. J Pediatr (1989) 2.80
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Missense mutations in MIP underlie autosomal dominant 'polymorphic' and lamellar cataracts linked to 12q. Nat Genet (2000) 2.77
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis (1996) 2.72
Antibiotic-resistant group JK bacteria in hospitals. J Clin Microbiol (1981) 2.71
Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother (2001) 2.68
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
Human mycoses: drugs and targets for emerging pathogens. Science (1994) 2.52
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol (1995) 2.51
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
The management of acute bronchiolitis. Thoracic Society of Australia and New Zealand. J Paediatr Child Health (1993) 2.30
Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol (2005) 2.29
An adaptation of Brislin's translation model for cross-cultural research. Nurs Res (2001) 2.28
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med (1986) 2.26
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Alpha-B crystallin gene (CRYAB) mutation causes dominant congenital posterior polar cataract in humans. Am J Hum Genet (2001) 2.19
Prevalence and clinical importance of sleep apnea in the first night after cerebral infarction. Neurology (2002) 2.16
Detection of Candida antigen in sera of patients with candidiasis by an enzyme-linked immunosorbent assay-inhibition technique. J Clin Microbiol (1979) 2.13
Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother (2001) 2.13
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood (1996) 2.12
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) (1986) 2.11
Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 2.11
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis (2000) 2.09
Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol (1998) 2.09
Factors associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr AIDS HIV Infect (1996) 2.09
Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol (1994) 2.07
Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J Pediatr (1990) 2.07
Heart rate variability dynamics during controlled hypotension with nicardipine, remifentanil and dexmedetomidine. Acta Anaesthesiol Scand (2013) 2.05
Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis (1994) 2.04
Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol (1987) 2.02
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (1998) 2.00
Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol (2009) 1.99
Effects of biatrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery. Circulation (2000) 1.98
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J Biol Chem (1998) 1.95
Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis (1988) 1.95
Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun (1993) 1.95
[A favorable response to the somatostatin analog SMS 201-995 in a patient with the carcinoid syndrome]. Rev Esp Enferm Dig (1991) 1.94
Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping. Neuroradiology (2004) 1.94
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 1.93
A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem (1999) 1.92
Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol (1988) 1.92
Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect (2001) 1.91
Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med (1988) 1.91
Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med (1988) 1.90
Sudden unexpected near death in epilepsy: malignant arrhythmia from a partial seizure. Neurology (2009) 1.87
Neuroendocrine and stress hormone changes during mirthful laughter. Am J Med Sci (1989) 1.86
Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr (1995) 1.86
Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis (2001) 1.86
Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. Am J Med (1982) 1.84
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.83
Neurotoxic effects of cisplatin therapy. Arch Neurol (1982) 1.83
Insertional mutagenesis in the extreme thermophilic eubacteria Thermus thermophilus HB8. Mol Microbiol (1992) 1.81
Ketamine sedation for children in the emergency department. Emerg Med (Fremantle) (2001) 1.78
Clinical and genetic heterogeneity in autosomal dominant cataract. Br J Ophthalmol (1999) 1.77
Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology (2004) 1.77
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology (1999) 1.76
Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart (2009) 1.76
Transmembrane ion fluxes during activation of human T lymphocytes: role of Ca2+, Na+/H+ exchange and phospholipid turnover. Immunol Rev (1987) 1.74
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology (2000) 1.72
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis (1992) 1.71